[A24-102] Atezolizumab (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V

Last updated 11.12.2024

Project no.:
A24-102

Commission:
Commission awarded on 27.09.2024 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission work started

Department/Division:
Drug Assessment

Topic:
Cancer

Project no.	Title	Status
A24-97	Atezolizumab (NSCLC) – Benefit assessment according to §35a Social Code Book V	Commission work started
A22-67	Atezolizumab (NSCLC) – Benefit assessment according to § 35a SGB V	Commission completed
A21-69	Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V	Commission completed
A20-97	Atezolizumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V	Commission completed
A19-86	Atezolizumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V	Commission completed
A19-84	Atezolizumab (NSCLC; combination with nab-paclitaxel and carboplatin) – Benefit assessment according to §35a Social Code Book V	Commission completed
A19-83	Atezolizumab (NSCLC; combination with bevacizumab, carboplatin and paclitaxel) – Benefit assessment according to §35a Social Code Book V	Commission completed
A19-81	Atezolizumab (breast cancer) - Benefit assessment according to §35a Social Code Book V	Commission completed
A18-88	Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V (new scientific findings)	Commission completed
A17-52	Atezolizumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V	Commission completed
A17-51	Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V	Commission completed
A17-50	Atezolizumab (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V	Commission completed

Contact

Press contact

+49 221 356850

presse@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form